UPJOHN's "INCYTE"-FUL INVESTMENT IN LIFESEQ GENOMICS DATABASE will cost the company $20 mil. under an agreement announced Dec. 1. The Upjohn entrance into gene therapy includes a $10 mil. fee for a non-exclusive subscription to Incyte's human genomics database and access to its high-throughput gene sequencing technology, and $10.1 mil. for a 10% equity stake in the Palo Alto, Calif.-based firm. Upjohn is purchasing 791,000 shares of Incyte common stock at $12.75 per share and will make milestone and royalty payments to Incyte on therapies issuing from their collaboration.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?